Schrodinger, Inc. (SDGR): Shareholders' Equity
$364.05M
As of 2025-12-31
$328.96M
As of 2026-06-30
-6.7%
3-year compound annual growth
-10.2%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $364.05M | -13.6% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $421.44M | -23.2% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $548.56M | +22.5% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $447.89M | -19.6% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $557.07M | -10.7% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $624.01M | n/m | 2022-02-24, Balance as of period end |
| 2019-12-31 | -$93.36M | n/a | 2021-03-04, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $433.90M | -22.8% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.02B | +22.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $52.45M | -24.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $37.21M | -47.5% |
Compare SDGR, ARVN, RCUS, LGND side by side · Screen every company in Pharmaceutical Preparations ↗